Bezafibrate is a well established pan-peroxisome proliferator-activated receptor (pan-PPAR) activator. This fibrate drug has over 25 years of therapeutic use with a good safety profile. The fibrate class of drugs are generally known as PPARα agonists, but bezafibrate appears to activate PPARδ and PPARγ as well. Bezafibrate activates human PPARα, PPARδ, and PPARγ with EC50 values of 50, 20, and 60 µM, respectively, in a cell-based transcription assay. Bezafibrate is used to treat hyperlipidemia. It helps lower low-density lipoprotein cholesterol and triglycerides while raising high-density lipoprotein cholesterol levels. It also improves insulin sensitivity and reduces blood glucose levels, which in combination with the cholesterol effects significantly lowers the incidence of cardiovascular events and development of diabetes in patients with features of metabolic syndrome.

Aleglitazar

Balaglitazone

Ciprofibrate

Clofibrate

Fenofibrate

FH535

GSK3787

GW 501516

GW1929

GW9662